PHD3 as a Prognosis Marker and its Relationship with Immune Infiltration in Lung Adenocarcinoma

Lung adenocarcinoma (LUAD) is a highly heterogeneous malignant tumor. Therefore, it is necessary to find predictive biomarkers related to the prognosis and immune infiltration of lung adenocarcinoma, which may provide an effective theoretical basis for its clinical treatment.

This study aimed to evaluate whether the expression level of PHD3 in lung adenocarcinoma (LUAD) is related to immunity.

PHD3 expression was analyzed by the ONCOMINE, TIMER, UALCAN, and GEPIA databases. The correlations between clinical information and PHD3 expression were analyzed by the LinkedOmics database. Then, we evaluated the influence of PHD3 on the survival of LUAD patients using Kaplan-Meier Plotter and HPA database. We explored the correlation between PHD3 and tumor immunity using TIMER and the correlation module of TISDIB. Finally, we used the cBioportal database to analyze PHD3 mutations in LUAD.

Comprehensive analysis displayed PHD3 expression to be clearly higher in LUAD compared to adjacent normal tissues. PHD3 expression was identified to be positively associated with tumor purity, histological type, and later pathological stage. Survival curve results revealed the high expression of PHD3 in LUAD patients to be accompanied by a poor prognosis. Further study indicated PHD3 to be significantly related to a variety of tumor immune cells and molecules. Moreover, among the LUAD cases with gene alteration of PHD3, amplification was the most common of all alteration types.

PHD3 may be used as a biomarker for survival and immunotherapy of LUAD.